BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23458426)

  • 1. Detection of pancreatic cancer using serum protein profiling.
    Velstra B; Bonsing BA; Mertens BJ; van der Burgt YE; Huijbers A; Vasen H; Mesker WE; Deelder AM; Tollenaar RA
    HPB (Oxford); 2013 Aug; 15(8):602-10. PubMed ID: 23458426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum peptide signatures for pancreatic cancer based on mass spectrometry: a comparison to CA19-9 levels and routine imaging techniques.
    Velstra B; Vonk MA; Bonsing BA; Mertens BJ; Nicolardi S; Huijbers A; Vasen H; Deelder AM; Mesker WE; van der Burgt YE; Tollenaar RA
    J Cancer Res Clin Oncol; 2015 Mar; 141(3):531-41. PubMed ID: 25240825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis.
    Guo J; Wang W; Liao P; Lou W; Ji Y; Zhang C; Wu J; Zhang S
    Cancer Sci; 2009 Dec; 100(12):2292-301. PubMed ID: 19775290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved classification of breast cancer peptide and protein profiles by combining two serum workup procedures.
    Velstra B; van der Burgt YE; Mertens BJ; Mesker WE; Deelder AM; Tollenaar RA
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):1983-92. PubMed ID: 22763645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reproducibility of serum protein profiling by systematic assessment using solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry.
    Callesen AK; Christensen Rd; Madsen JS; Vach W; Zapico E; Cold S; Jørgensen PE; Mogensen O; Kruse TA; Jensen ON
    Rapid Commun Mass Spectrom; 2008; 22(3):291-300. PubMed ID: 18181248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers screening between preoperative and postoperative patients in pancreatic cancer.
    Li P; Yang J; Ma QY; Wu Z; Huang C; Li XQ; Wang Z
    Asian Pac J Cancer Prev; 2013; 14(7):4161-5. PubMed ID: 23991970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA-Binding Motif Protein 6 is a Candidate Serum Biomarker for Pancreatic Cancer.
    Duan B; Hu X; Fan M; Xiong X; Han L; Wang Z; Tong D; Liu L; Wang X; Li W; Yang J; Huang C
    Proteomics Clin Appl; 2019 Sep; 13(5):e1900048. PubMed ID: 31207145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis.
    Xue A; Scarlett CJ; Chung L; Butturini G; Scarpa A; Gandy R; Wilson SR; Baxter RC; Smith RC
    Br J Cancer; 2010 Jul; 103(3):391-400. PubMed ID: 20588270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Application of serum protein profiling in diagnosis, prognosis and evaluation of curative effect of pancreatic adenocarcinoma].
    Guo JH; Wang WJ; Liao P; Zhang CY; Jin DY; Lou WH; Zhang SC
    Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):33-6. PubMed ID: 20211064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.
    Fiedler GM; Leichtle AB; Kase J; Baumann S; Ceglarek U; Felix K; Conrad T; Witzigmann H; Weimann A; Schütte C; Hauss J; Büchler M; Thiery J
    Clin Cancer Res; 2009 Jun; 15(11):3812-9. PubMed ID: 19470732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Commonality and differences of methylation signatures in the plasma of patients with pancreatic cancer and colorectal cancer.
    Melson J; Li Y; Cassinotti E; Melnikov A; Boni L; Ai J; Greenspan M; Mobarhan S; Levenson V; Deng Y
    Int J Cancer; 2014 Jun; 134(11):2656-62. PubMed ID: 24288256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
    Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
    BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a high molecular weight kininogen fragment as a marker for early gastric cancer by serum proteome analysis.
    Umemura H; Togawa A; Sogawa K; Satoh M; Mogushi K; Nishimura M; Matsushita K; Tanaka H; Takizawa H; Kodera Y; Nomura F
    J Gastroenterol; 2011 May; 46(5):577-85. PubMed ID: 21298293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic classification of pancreatic adenocarcinoma tissue using protein chip technology.
    Scarlett CJ; Smith RC; Saxby A; Nielsen A; Samra JS; Wilson SR; Baxter RC
    Gastroenterology; 2006 May; 130(6):1670-8. PubMed ID: 16697731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry.
    Liu XP; Shen J; Li ZF; Yan L; Gu J
    Cancer Invest; 2006 Dec; 24(8):747-53. PubMed ID: 17162557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of lung adenocarcinoma using magnetic beads based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry serum protein profiling.
    Lin XL; Yang SY; Du J; Tian YX; Bu LN; Huo SF; Wang FP; Nan YD
    Chin Med J (Engl); 2010 Jan; 123(1):34-9. PubMed ID: 20137572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
    Yoneyama T; Ohtsuki S; Honda K; Kobayashi M; Iwasaki M; Uchida Y; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Huang W; Yamada T; Tachikawa M; Terasaki T
    PLoS One; 2016; 11(8):e0161009. PubMed ID: 27579675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a decision tree model for diagnosis of early rheumatoid arthritis by proteomic fingerprinting.
    Li Y; Sun X; Zhang X; Liu Y; Yang Y; Li R; Liu X; Jia R; Li Z
    Int J Rheum Dis; 2015 Nov; 18(8):835-41. PubMed ID: 26249836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer.
    Zhao YP; Zhou PT; Ji WP; Wang H; Fang M; Wang MM; Yin YP; Jin G; Gao CF
    Clin Exp Med; 2017 Feb; 17(1):9-18. PubMed ID: 26714469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
    Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J
    World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.